BANK VONTOBEL/CALL/EDWARDS LIFESCIENCES/86/0.1/20.09.24 | Delayed Deutsche Boerse AG 08:33:54 27/06/2024 pm IST | ||
| 0.97 EUR | +12.79% |
|
| Current month | +43.33% | ||
| 1 month | +22.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 0.97 | +12.79% |
| 26/24/26 | 0.86 | +6.17% |
| 25/24/25 | 0.81 | -1.22% |
| 24/24/24 | 0.82 | +2.50% |
| 21/24/21 | 0.8 | -1.23% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 08:33 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Vontobel
|
| WKN | VM7PAS |
| ISIN | DE000VM7PAS3 |
| Date issued | 29/12/2023 |
| Strike | 86 $ |
| Maturity | 20/09/2024 (85 Days) |
| Parity | 10 : 1 |
| Emission price | 0.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.46 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.01 € |
| Spread % | 1.00% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
91.56
USD
Average target price
96.05
USD
Spread / Average Target
+4.91%
- Stock Market
- Warrants
- Warrant
